Amgen
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Amgen sits in the top decile of US sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count).
Amgen: 558 sponsored US clinical trials, 55 recruiting.
Amgen sponsors 558 registered US clinical trials on ClinicalTrials.gov, 55 of them currently recruiting, and 373 completed. 212 of these trials are in Phase 3-4 (later-stage) and 327 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 8 trials.
Top-decile sponsor footprint
Amgen ranks in the top decile of sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
373 of 461 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
558 total, page 2 of 12
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717
Aimovig Pregnancy Exposure Registry
NCT06150781
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
NCT04521231
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
NCT03633708
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
NCT07313761
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
NCT07229157
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
NCT07226778
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
NCT06660173
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
NCT06527404
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
NCT06376045
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
NCT06312020
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
NCT06224192
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT06180278
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
NCT06229145
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06131398
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
NCT05975073
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05284747
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT05361395
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
NCT05322577
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
NCT05198934
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
NCT05111626
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05052801
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497
Myasthenia Gravis Inebilizumab Trial
NCT04524273
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
NCT04303780
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
NCT03836040
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
NCT03600883
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
NCT03319940
The Effect of AMG 133 on Gastric Emptying
NCT07429032
Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants
NCT06910709
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
NCT07428525
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 216 |
| Phase 2 | 111 |
| Phase 3 | 174 |
| Phase 4 | 38 |
What is open in the Amgen pipeline
55 recruiting of 558 indexed (10% open); 373 completed (67%).
Phase mix: 212 late (III/IV) vs 327 early (I/II) (early-phase heavy).
Top condition: Obesity (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Amgen: open-pipeline peers nationwide
Peers matched on 558 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Amgen sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 558 trials (± recruiting share)
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Ohio State University · 552 trials · 21% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Ohio University · 10% recruiting · 51 trials
- Purdue University · 10% recruiting · 141 trials
- University of North Carolina, Chapel Hill · 10% recruiting · 1,109 trials
- Abiomed · 10% recruiting · 20 trials
Related
What to do with this Amgen page
558 registered trials is a research-attention snapshot, not an endorsement of Amgen or any single study.
- 55 of Amgen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Amgen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Amgen pipeline card: 558 registered trials from official public datasets.Report a data error.